Charity Ratings
Charity Navigator: CureSearch has earned a Four-Star rating with Charity Navigator, which notes: "If this organization aligns with your passions and values, you can give with confidence. This overall score is calculated from multiple beacon scores, weighted as follows: 80% Accountability & Finance, 10% Leadership & Adaptability, 10% Culture & Community."
GuideStar: CureSearch is a Platinum participant in the GuideStar Exchange program. Participation allows us to update key information directly to GuideStar so it is available to its millions of users on a regular basis. It provides richer and broader information about our programs, impact, finances, people and more. CureSearch has provided evidence of impact, financial data, IRS Forms 990 and our mission objectives.
BBB Wise Giving Alliance: BBB Wise Giving Alliance has twenty standards by which they measure a charity’s accountability. Those standards include having an effectiveness policy and report, an audit and annual report, truthful materials, and a donor privacy policy. CureSearch meets 20 of the 20 standards.
GreatNonprofits: CureSearch has earned a spot on the 2023 Top Rated List! GreatNonprofits' Top-Rated Nonprofits are endorsed by clients, volunteers, and their community who have shared inspiring testimonials about our their personal experience with us.
Making an Impact
Only research will spark new discoveries in childhood cancer, leading to clinical trial options for patients today and ultimately, to less-toxic treatments for patients around the world. We know that our volunteers and donors place their trust in us to identify and fund the most innovative research projects while effectively managing expenses to maximize program support.
In 2023, 70% of our expenses were allocated to programs, primarily research grants across our three research funding arms: Young Investigator, Acceleration Initiative and Catapult Awards. For 2024, we anticipate that our program investment will exceed 70% of total expenses.
Our active projects include Dr. Mohamed Abdelbaki’s clinical trial at Washington University, which is testing a novel immunotherapy to treat recurrent brain tumors, and Dr. Bruenig’s preclinical work at Cedars-Sinai, which aims to change the treatment landscape for children with incurable brain tumors. These projects, and others like them, highlight our dedication to advancing research that will quickly develop new treatment options for children with cancer.
We are grateful to the donors, fundraisers, and volunteers who support our shared mission to end children’s cancer, and we are committed to stewarding every dollar raised toward the greatest impact on the children, adolescents, and young adults who are depending on us.
Annual Reports
Audited Financial Statements
- Fiscal Year 2023 Audited Financial Statements for period ending 12/31/23
- Fiscal Year 2022 Audited Financial Statements for period ending 12/31/22
- Fiscal Year 2021 Audited Financial Statements for period ending 12/31/21
- Fiscal Year 2020 Audited Financial Statements for period ending 12/31/20
Federal 990 Tax Forms
